Details of the Drug

General Information of Drug (ID: DMNSAND)

Drug Name
Evolocumab
Synonyms Repatha
Indication
Disease Entry ICD 11 Status REF
Heterozygous familial hypercholesterolemia 5C80.00 Approved [1]
Homozygous familial hypercholesterolemia 5C80.00 Approved [1]
Hypercholesterolaemia 5C80.0 Approved [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D8MNH5
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Heterozygous familial hypercholesterolemia
ICD Disease Classification 5C80.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website.
2 Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynol Pol. 2023;74(3):234-242.
3 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722.